The Prevail DCB has been cleared to use in dozens of countries around the globe, but it has not yet been approved by the FDA.

"The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high.

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.

Researchers believe a new robotic TEE system could improve the long-term health of interventional echocardiographers in addition to several other key benefits.

One of the world's largest medtech companies could make a major move within the next 18 months. Que Dallara, the current president of Medtronic’s diabetes business, would be the new company's CEO.

While LVOT modification does make these procedures longer, it can help high-risk patients avoid systolic anterior motion.

Gregg Fonarow, MD, discussed the American Heart Association's stroke guidelines, the growing influence of AI and much more.